Cargando…

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

OBJECTIVE: Hypoglycemia is associated with an increased risk of cardiovascular disease including cardiac arrhythmias. We investigated the effect of hypoglycemia in the setting of acute glycemic fluctuations on cardiac rhythm and cardiac repolarization in insulin-treated patients with type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, Andreas, Bagger, Jonatan I, Baldassarre, Maria P A, Christensen, Mikkel B, Abelin, Kirsten U, Faber, Jens, Pedersen-Bjergaard, Ulrik, Holst, Jens J, Lindhardt, Tommi B, Gislason, Gunnar, Knop, Filip K, Vilsbøll, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345897/ https://www.ncbi.nlm.nih.gov/pubmed/34085953 http://dx.doi.org/10.1530/EJE-21-0232

Ejemplares similares

Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study
por: Andersen, Andreas, et al.
Publicado: (2021)

Acute changes in plasma glucose increases left ventricular systolic function in insulin‐treated patients with type 2 diabetes and controls
por: Andersen, Andreas, et al.
Publicado: (2022)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Hypoglycaemia and cardiac arrhythmias in diabetes
por: Andersen, Andreas, et al.
Publicado: (2020)

Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial
por: Kristensen, Peter Lommer, et al.
Publicado: (2013)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

The effect of curcumin on hepatic fat content in individuals with obesity
por: Hellmann, Pernille H., et al.
Publicado: (2022)

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity
por: Hellmann, Pernille H, et al.
Publicado: (2023)

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
por: Fotheringham, Amelia K., et al.
Publicado: (2020)

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
por: Mathiesen, David S., et al.
Publicado: (2021)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
por: Junker, Anders Ellekær, et al.
Publicado: (2014)

High‐Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta‐Adrenoceptor Blockade: A Randomized Clinical Trial
por: Petersen, Kasper M., et al.
Publicado: (2020)

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
por: Hagemann, Christoffer A., et al.
Publicado: (2022)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
por: Mathiesen, David S, et al.
Publicado: (2020)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course
por: Mikkelsen, Kristian H., et al.
Publicado: (2018)

Decreased branched-chain amino acids and elevated fatty acids during antecedent hypoglycemia in type 1 diabetes
por: She, Rui, et al.
Publicado: (2023)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Effects of levothyroxine substitution therapy on hunger and food intake in individuals with hypothyroidism
por: Medici, Bjarke R, et al.
Publicado: (2023)

Association of IGF1 with glycemic control and occurrence of severe hypoglycemia in patients with type 1 diabetes mellitus
por: Færch, Louise, et al.
Publicado: (2012)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Patients with atrial fibrillation and permanent pacemaker: Temporal changes in patient characteristics and pharmacotherapy
por: Dalgaard, Frederik, et al.
Publicado: (2018)

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Storgaard, Heidi, et al.
Publicado: (2016)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Thyroid dysfunction and electrocardiographic changes in subjects without arrhythmias: a cross-sectional study of primary healthcare subjects from Copenhagen
por: Tayal, Bhupendar, et al.
Publicado: (2019)

Risk factors and a 3-month risk score for predicting pacemaker implantation in patients with atrial fibrillation
por: Dalgaard, Frederik, et al.
Publicado: (2020)

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)
por: Christensen, Alexander S., et al.
Publicado: (2020)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vjjfb81js51qmc0gp4ea462keu